1.
J Drugs Dermatol
; 22(12): e42-e43, 2023 12 01.
Article
in English
| MEDLINE
| ID: mdl-38051828
ABSTRACT
Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis. J Drugs Dermatol. 2023;22(12):e42-e43. doi:10.36849/JDD.6532e.